1 / 1

ZOLADEX(Goserelin)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

IMPLANT

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Goserelin Acetate Implant (ZOLADEX®) is a sustained-release GnRH agonist used to suppress testosterone in prostate cancer. Administered subcutaneously every 12 weeks, it induces medical castration, slowing tumor progression. Key indications include locally advanced (Stage B2-C) and metastatic prostate cancer, often combined with radiation or flutamide. Risks include tumor flare, cardiovascular events, and injection site injury. Monitoring testosterone levels and managing hyperglycemia are critical during therapy.

Generic name

ZOLADEX(Goserelin)

English name

Goserelin

Alternative Names

ZOLADEX

Drug prices

Indications

Locally Confined Prostate Cancer (Stage B2–C): Used in combination with flutamide and radiotherapy. Initiated 8 weeks prior to radiation and continued during therapy.

Advanced Prostate Cancer: Palliative treatment for metastatic disease

Therapeutic Target

Gonadotropin-Releasing Hormone (GnRH) receptors in the pituitary gland. Suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to testosterone reduction to castration levels.

Active Ingredients

Goserelin acetate (11.3 mg per implant, equivalent to 10.8 mg goserelin).

Dosage form

IMPLANT

specifications

Sealed aluminum foil laminate pouch with desiccant; store at ≤25°C (77°F).

Description

Chemical Structure: Synthetic decapeptide GnRH analog ([D-Ser(Bu⁶),Azgly¹⁰]).

Matrix: Biodegradable D,L-lactic and glycolic acids copolymer (36.0 mg total implant weight).

Release Profile: Sustained release over 12 weeks.

Dosage and Administration

Dose: 10.8 mg administered subcutaneously every 12 weeks.

Site: Anterior abdominal wall below the navel line.

Technique:

Aseptic technique; avoid muscle/peritoneum penetration.

Insert needle at 30–45° angle; no aspiration required.

Monitor for vascular injury (risk in low BMI or anticoagulated patients).

Missed Dose: Adhere to 12-week schedule; brief delays permissible.

CATEGORY NAVIGATION